Alnylam Pharmaceuticals shares are trading lower after the company announced it received a Complete Response Letter from the FDA for its sNDA for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis.
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals has received a Complete Response Letter from the FDA for its sNDA for patisiran, a treatment for the cardiomyopathy of ATTR amyloidosis. This has resulted in a decrease in the company's share price.
October 09, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Alnylam Pharmaceuticals' stock price is trading lower after the company received a Complete Response Letter from the FDA for its sNDA for patisiran.
The FDA's Complete Response Letter is a form of regulatory setback, indicating that the agency has completed its review of a new drug application but issues remain that preclude the approval of the application in its current form. This news is directly related to Alnylam Pharmaceuticals and is likely to negatively impact investor sentiment, leading to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100